Viridian Therapeutics, Inc. , a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today reported recent ...

Lonigutamab (VB-421) is a subcutaneously delivered anti-IGF-1R that is currently being evaluated in a phase 1 study for thyroid eye disease. It is estimated to be a market opportunity worth over ...

The researchers showed “super antibodies” from the man’s blood prevented toxic damage from neurotoxins found in the venoms of 19 different snake species, including mambas and cobras.

In particular, the demise of immuno-oncology drug cabiralizumab – an anti-CSF-1R antibody previously partnered with Bristol-Myers Squibb that failed a pancreatic cancer trial earlier this year ...

Teprotumumab (Tepezza), a fully human insulin-like growth factor type 1 receptor—inhibitory monoclonal antibody, was recently approved for treatment of thyroid eye disease. It is the first treatment ...

At close: May 2 at 4:00:01 PM EDT ...